--------- Forwarded message ----------
From: "WE MOVE" <[log in to unmask]>
Date: Tue, 25 May 2004 18:08:57 -0400
Subject: Dopamine Agonists for PD (AAN 2004)
Tuesday, May 25, 2004 Issue 22 VOLUME 1 ISSUE 22
-------------------------------------------------------------------------
-------
ARCHIVE
Issue 20
May 24, 2004
Vol. 1 Issue 20
Piribedil for de novo PD (AAN 2004)
E-MOVE reports from the American Academy of Neurology, San Francisco
April 25-30, 2004. Page (A), session (S) and poster (P) numbers are from
Neurology 2004;62(7), Suppl 5
Piribedil efficacy in monotherapy (150 to 300 mg/day) in de novo
parkinsonian patients: Planned 6-month analysis of the 2-year
Parkinson-Regain study
A Lees, O Gershanik, O Blin, M Behari, E Otero, J Ferreira, M Aguilar, B
Kies, A Castro Caldas, N Bodjarian, O Rascol
Four hundred-one de novo PD patients were randomized to receive placebo
or piribedil titrated to a maximum of 300 mg/day. At 6 months,
significant differences favoring piribedil were seen for tremor,
rigidity, bradykinesia, and axial score, as well as total UPDRS motor
score, which rose by 2.5 points in placebo-treated patients, and fell by
5 points in piribedil-treated patients (p<0.0001). Gastrointestinal
disorders were more common in piribedil-treated patients, as were
anxiety, depression, and sleep disorders.
[FULL STORY]
http://www.imakenews.com/wemove/e_article000263776.cfm?x=b3bwd9F,b1Qs8yH
9
Valve Disease from Pergolide (AAN 2004)
E-MOVE reports from the American Academy of Neurology, San Francisco
April 25-30, 2004. Page (A), session (S) and poster (P) numbers are from
Neurology 2004;62(7), Suppl 5
Chronic treatment with pergolide for Parkinson's disease is associated
with significant cardiac valve regurgitation
RB Dewey, DG Baseman, PE O'Suilleabhain, SC Reimold, JG Baseman, SR
Laskar
P04.142, A331-332
Echocardiograms of 46 patients treated with pergolide indicated that 89%
had some degree of valvular insufficiency. The most significant increase
was for the tricuspid valve, for which regurgitation risk was 14-fold
higher than in non-PD controls. Four patients developed clinically
significant regurgitation, which improved on echocardiography 7 months
after drug withdrawal.
[end]
[FULL STORY]
http://www.imakenews.com/wemove/e_article000263777.cfm?x=b3bwd9F,b1Qs8yH
9
Apomorphine for Off Episodes (AAN 2004)
E-MOVE reports from the American Academy of Neurology, San Francisco
April 25-30, 2004. Page (A), session (S) and poster (P) numbers are from
Neurology 2004;62(7), Suppl 5
A double-blind placebo-controlled study of the efficacy of a single dose
of subcutaneous apomorphine in Parkinson's disease
AC Koller, APO303 Investigators
P04.135, A329
Fifty-six PD patients with multiple daily off periods received a single
injection of apomorphine at each of a series of visits, with dose
escalated from 2 mg to 10 mg. At visit 2, patients received either
placebo or 4 mg apomorphine, with the alternate treatment at visit 3.
Patients received trimethobenzamide before treatment initiation. Onset of
apomorphine effect was within 20 minutes, with benefit extending at least
90 minutes. UPDRS improvement versus baseline was 8-14 points at 20-40
minutes, and 5 points at 90 minutes, while placebo treatment produced
little or no response. Forty-four patients were titrated as high as 6 mg,
25 to 8 mg, and 14 to 10 mg. Yawning, dizziness, and nausea were the most
common adverse events.
[end]
[FULL STORY]
http://www.imakenews.com/wemove/e_article000263778.cfm?x=b3bwd9F,b1Qs8yH
9
----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn
